- Home
- LFS vs MREO Comparison
LFS vs MREO Comparison
Compare LFS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFS | MREO |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 50.3M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LFS | MREO |
|---|---|---|
| Price | $2.18 | $0.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 1.4M | ★ 4.9M |
| Earning Date | 04-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $0.20 |
| 52 Week High | $12.49 | $2.37 |
Technical Indicators
Market Signals| Indicator | LFS | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 41.21 |
| Support Level | $2.11 | $0.22 |
| Resistance Level | $2.33 | $0.35 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 28.36 | 23.45 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).